No Data
No Data
No Data
Craig-Hallum Sticks to Their Buy Rating for Avid Bioservices (CDMO)
Avid Bioservices to Participate at Upcoming Investor Conferences
TUSTIN, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient li
Avid Bioservices Currently Up 11 Consecutive Days, on Track for Longest Winning Streak on Record -- Data Talk
Avid Bioservices, Inc. (CDMO) is currently at $8.37, up $0.12 or 1.45% --Would be highest close since March 6, 2024, when it closed at $8.79 --Currently up 11 consecutive days; up 30.99% over this p
Avid Bioservices Is Maintained at Outperform by RBC Capital
Avid Bioservices Is Maintained at Outperform by RBC Capital
Royal Bank of Canada: Maintaining the Avid Bioservices (CDMO.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $7.00 to $8.00.
Royal Bank of Canada: Maintaining the Avid Bioservices (CDMO.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $7.00 to $8.00.
RBC Capital Maintains Outperform on Avid Bioservices, Raises Price Target to $8
RBC Capital analyst Sean Dodge maintains Avid Bioservices (NASDAQ:CDMO) with a Outperform and raises the price target from $7 to $8.
No Data